Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is meant to assess the safety and efficacy of rAAV2-ND4 treatment of Leber hereditary optic neuropathy with 11778 LHON mutation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bin Li
• Collaborator: Huazhong University of Science and Technology

Criteria

Inclusion Criteria:

1. comply with Leber hereditary optic neuropathy diagnostic criteria.

2. in patients with informed consent, voluntary participation.

3. signed informed consent.

4. 8 ≤ Age ≤ 60 years old, good health, the patient can tolerate local anesthesia surgery.

5. to comply with doctor's instructions, can in the time of referral.

Exclusion Criteria:

1. Cardiopulmonary and renal function in severe weakness, cancer, a variety of bleeding disorders, acute sensing disease, high fever, high fever disease, women during pregnancy, heart disease, such as post-operative recovery period.

2. Are participating in other clinical studies of patients.

3. Patients with mental disorders.